Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Plain-language summary
This Phase 3 trial is comparing Soquelitinib, Belinostat, and other medications against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is widely available at 21 US locations.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Soquelitinib (DRUG): Soquelitinib 200 mg tablets will be taken by mouth two times a day | Belinostat (DRUG): Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle | Pralatrexate (DRUG): Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
- Drugs / treatments
- Soquelitinib, Belinostat, Pralatrexate
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details